PainPhase 4NCT05991375
Comparison of Efficacy of Bupivacaine in Supraclavicular Block With or Without Dexmedetomidine
A Phase 4 study testing DEXmedetomidine and saline in people with Pain, run by Sindh Institute of Urology and Transplantation at 1 site in Pakistan.
Trial summary
End-stage renal disease (ESRD) patients are coming for Brachial vein transposition surgery. Patients were randomly allocated using sealed opaque envelope bearing A- (Injection bupivacaine (0.25%) 28 ml plus 2 ml. normal saline) and B-Injection bupivacaine (0.25%) 28 mL plus dexmedetomidine I ug/kg diluted to 2 ml). Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Pain
- What is being tested?
- DEXmedetomidine and saline
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 108 participants
- Where
- 1 sitePakistan
- Study dates
- 15 Feb 2021to 30 Apr 2021
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Chronic renal failure patients who will undergo elective basilic vein transposition surgery
- Either gender
- ASA III
- Age 18-65 years.
Who cannot join
- Mentally challenged
- Pregnancy.
- Hypersensitivity to bupivacaine or dexmedetomidine
- Seizures
- Neck swelling (hematoma, lipoma, tumor, thyroid)
- Neuromuscular dystrophy
- Bleeding disorders
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized Comparative Evaluation Of The Effects Of Dexmedetomidine As An Adjuvant With Bupivacaine In Supraclavicular Block In Chronic Renal Failure Patients Undergoing Basilic Vein Transposition Surgery
End-stage renal disease (ESRD) patients are coming for Brachial vein transposition surgery. Patients were randomly allocated using sealed opaque envelope bearing A- (Injection bupivacaine (0.25%) 28 ml plus 2 ml. normal saline) and B-Injection bupivacaine (0.25%) 28 mL plus dexmedetomidine I ug/kg diluted to 2 ml).
Supraclavicular block under ultrasound and nerve stimulator guidance was performed.
Read the detailed description
This study was conducted after approval of the institutional ethical review committee and then from College of Physicians and Surgeons Pakistan. Patients with end stage renal disease (ESRD) coming for Brachial vein transposition surgery, and fulfilling the inclusion criteria were enrolled in this study. All patients were instructed not to consume solid food after midnight prior to surgery. A brief history of demographic data was taken from each patient. Each participant's height in meters was measured using wall mounted scale, weight in kg using a weighing machine, and BMI kg/m² was noted prior to operation. The findings of quantitative variables (age, height, weight, sensory blockade, motor blockade and qualitative variables (gender, diabetes mellitus type II, hypertension, and dyslipidemia) were entered in the proforma attached as an annexure. Patients were randomly allocated using sealed opaque envelope bearing A- (Injection bupivacaine (0.25%) 28 ml plus 2 ml. normal saline) and B-Injection bupivacaine (0.25%) 28 mL plus dexmedetomidine I ug/kg diluted to 2 ml). Only the anaesthesiologists for the specific case were aware of the treatment allocation until the end of the surgical procedure. The investigator for assessing the block and the other outcome variables, remained blinded to the patient's group allocation.
Routine monitoring of heart rate \& rhythm by ECG, and arterial blood pressure using non-invasive blood pressure (NIBP) including systolic, diastolic \& mean arterial blood pressure, and peripheral oxygen saturation (SPO2) using a pulse oximeter was performed on each patient. The supraclavicular brachial plexus block was performed under the supervision of a consultant anaesthesiologist in a supine position with a head up to 45 degrees. An Intravenous (IV) line was established and the skin was disinfected and a linear probe, high frequency 12 MHz was placed firmly over the supraclavicular fossa, the probe was positioned in the transverse plane immediately superior to the clavicle at approximately its midpoint. The probe was tilted caudally to obtain a cross sectional view of the subclavian artery. The brachial plexus was seen as a collection of hypo-echoic oval structures lateral and superficial to the artery. Using a 25 gauge needle 1 to 2 ml of 2% lidocaine was locally infiltrated into the skin 1 cm lateral to the probe to decrease the discomfort during needle insertion. A 50 mm or 80 mm length, short bevel, insulated nerve stimulator needle was used. Peripheral nerve stimulation (PNS) is an additional way of confirming nerve location. Initial settings was set at 0.5 mA current, 2 Hz frequency, and pulse width of 0.1 milliseconds. Close approximation to the divisions of brachial plexus was confirmed by getting nerve stimulation on 0.3 mA current. The needle was advanced along the long axis in the same plane as the ultrasound beam. The shaft and tip was visualized in real time as the needle was advanced towards the target nerves. The drug in either group was injected under direct vision of ultrasound beams and by confirming with nerve stimulation. Sensory blockade and motor blockade was assessed every 3 minutes. Time of onset of sensory and motor blockade and duration of sensory and motor blockade were noted as per operational definition. Postoperative pain was assessed with visual analogue scale (VAS). Patients were asked to mark a point on the line that matches the intensity of pain on the Visual Analogue Score hourly for 4 hours post operatively. Those patients having arm pain equal to or greater than 4 on VAS, were given rescue analgesic (inj. Paracetamol (15mg/kg 1/V) and duration of analgesia were noted as per operational definition.
- Conditions
- Pain
- Being tested
- DEXmedetomidine, saline
- Medical subject headings
- Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DEXmedetomidineDrug
Also called DEX
28 mL of Bupivacain 0.25% was mixed with Dexmedetomidine 1 microgram/kg body weight mixed in 2 mL = total volume 30 mL
salineOther
28 mL of Bupivacain 0.25% was mixed with 2 mL of Normal saline = total volume 30 mL
| Study group | Role | What they receive |
|---|---|---|
| BUPIvacaine 0.25% | Active comparator | (Injection bupivacaine (0.25%) 28 ml plus 2 ml. normal saline) making a total volume of local anaesthetic solution equal to 30 mL Receives: Other: saline |
| Bupivacaine0.25%+DEX | Experimental | Injection bupivacaine (0.25%) 28 mL plus dexmedetomidine I ug/kg diluted to 2 ml) making a total volume of local anaesthetic solution equal to 30 mL Receives: Drug: DEXmedetomidine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain score
Visual Analogue Scale for pain
0-1-2-3-4-5-6-7-8-9-10
Pain score 0 means no pain, Pain score 1 to 3 means mild pain, Pain score 4-6 means moderate pain, Pain score 7-9 means severe pain, Pain score 10 means most excruciating pain one can have,
Measured: 0-4 hours
Heart rate
Heart rate as per vitals monitoring device
Measured: 0-4 hours
Mean blood pressure
as measured by non-invasive blood pressure monitoring device
Measured: 0-4 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2023
- Study start15 Feb 2021
- Primary completion30 Apr 2021
- Study completion30 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 108 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sindh Institute of Urology and Transplantation
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Syed Muhammad Abbas, Sindh Institute of Urology and Transplantation
- Investigators
- Fauzia Ali, FCPS, Study chair, Professor Dept of Anaesthesiology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05991375
- Sponsor's protocol ID
- SIUT-ERC-2020/PA-257
- Status last verified
- Aug 2023
- First submitted
- 29 Jul 2023
- Last updated
- 14 Aug 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Comparative Evaluation Of The Effects Of Dexmedetomidine As An Adjuvant With Bupivacaine In Supraclavicular Block In Chronic Renal Failure Patients Undergoing Basilic Vein Transposition Surgery
- ClinicalTrials.gov ID
- NCT05991375
- Acronym / sponsor ID
- SIUT-ERC-2020/PA-257
- Conditions
- Pain
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 108 participants (actual)
- Lead sponsor
- Sindh Institute of Urology and TransplantationUniversity, hospital or other
- Study start
- 15 Feb 2021 (actual)
- Primary completion
- 30 Apr 2021 (actual)
- Study completion
- 30 Apr 2021 (actual)
- First posted
- 14 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
End-stage renal disease (ESRD) patients are coming for Brachial vein transposition surgery. Patients were randomly allocated using sealed opaque envelope bearing A- (Injection bupivacaine (0.25%) 28 ml plus 2 ml. normal saline) and B-Injection bupivacaine (0.25%) 28 mL plus dexmedetomidine I ug/kg diluted to 2 ml).
Supraclavicular block under ultrasound and nerve stimulator guidance was performed.
Detailed description
This study was conducted after approval of the institutional ethical review committee and then from College of Physicians and Surgeons Pakistan. Patients with end stage renal disease (ESRD) coming for Brachial vein transposition surgery, and fulfilling the inclusion criteria were enrolled in this study. All patients were instructed not to consume solid food after midnight prior to surgery. A brief history of demographic data was taken from each patient. Each participant's height in meters was measured using wall mounted scale, weight in kg using a weighing machine, and BMI kg/m² was noted prior to operation. The findings of quantitative variables (age, height, weight, sensory blockade, motor blockade and qualitative variables (gender, diabetes mellitus type II, hypertension, and dyslipidemia) were entered in the proforma attached as an annexure. Patients were randomly allocated using sealed opaque envelope bearing A- (Injection bupivacaine (0.25%) 28 ml plus 2 ml. normal saline) and B-Injection bupivacaine (0.25%) 28 mL plus dexmedetomidine I ug/kg diluted to 2 ml). Only the anaesthesiologists for the specific case were aware of the treatment allocation until the end of the surgical procedure. The investigator for assessing the block and the other outcome variables, remained blinded to the patient's group allocation.
Routine monitoring of heart rate \& rhythm by ECG, and arterial blood pressure using non-invasive blood pressure (NIBP) including systolic, diastolic \& mean arterial blood pressure, and peripheral oxygen saturation (SPO2) using a pulse oximeter was performed on each patient. The supraclavicular brachial plexus block was performed under the supervision of a consultant anaesthesiologist in a supine position with a head up to 45 degrees. An Intravenous (IV) line was established and the skin was disinfected and a linear probe, high frequency 12 MHz was placed firmly over the supraclavicular fossa, the probe was positioned in the transverse plane immediately superior to the clavicle at approximately its midpoint. The probe was tilted caudally to obtain a cross sectional view of the subclavian artery. The brachial plexus was seen as a collection of hypo-echoic oval structures lateral and superficial to the artery. Using a 25 gauge needle 1 to 2 ml of 2% lidocaine was locally infiltrated into the skin 1 cm lateral to the probe to decrease the discomfort during needle insertion. A 50 mm or 80 mm length, short bevel, insulated nerve stimulator needle was used. Peripheral nerve stimulation (PNS) is an additional way of confirming nerve location. Initial settings was set at 0.5 mA current, 2 Hz frequency, and pulse width of 0.1 milliseconds. Close approximation to the divisions of brachial plexus was confirmed by getting nerve stimulation on 0.3 mA current. The needle was advanced along the long axis in the same plane as the ultrasound beam. The shaft and tip was visualized in real time as the needle was advanced towards the target nerves. The drug in either group was injected under direct vision of ultrasound beams and by confirming with nerve stimulation. Sensory blockade and motor blockade was assessed every 3 minutes. Time of onset of sensory and motor blockade and duration of sensory and motor blockade were noted as per operational definition. Postoperative pain was assessed with visual analogue scale (VAS). Patients were asked to mark a point on the line that matches the intensity of pain on the Visual Analogue Score hourly for 4 hours post operatively. Those patients having arm pain equal to or greater than 4 on VAS, were given rescue analgesic (inj. Paracetamol (15mg/kg 1/V) and duration of analgesia were noted as per operational definition.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BUPIvacaine 0.25% | Active comparator | Other: saline(Injection bupivacaine (0.25%) 28 ml plus 2 ml. normal saline) making a total volume of local anaesthetic solution equal to 30 mL |
| Bupivacaine0.25%+DEX | Experimental | Drug: DEXmedetomidineInjection bupivacaine (0.25%) 28 mL plus dexmedetomidine I ug/kg diluted to 2 ml) making a total volume of local anaesthetic solution equal to 30 mL |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Chronic renal failure patients who will undergo elective basilic vein transposition surgery
- Either gender
- ASA III
- Age 18-65 years.
Key exclusion criteria (7 listed)
- Mentally challenged
- Pregnancy.
- Hypersensitivity to bupivacaine or dexmedetomidine
- Seizures
- Neck swelling (hematoma, lipoma, tumor, thyroid)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DEXmedetomidineAlso: DEX28 mL of Bupivacain 0.25% was mixed with Dexmedetomidine 1 microgram/kg body weight mixed in 2 mL = total volume 30 mL | Drug | Bupivacaine0.25%+DEX |
| saline28 mL of Bupivacain 0.25% was mixed with 2 mL of Normal saline = total volume 30 mL | Other | BUPIvacaine 0.25% |
Primary outcome
Pain score
Time frame: 0-4 hours
Visual Analogue Scale for pain 0-1-2-3-4-5-6-7-8-9-10 Pain score 0 means no pain, Pain score 1 to 3 means mild pain, Pain score 4-6 means moderate pain, Pain score 7-9 means severe pain, Pain score 10 means most excruciating pain one can have,
Heart rate
Time frame: 0-4 hours
Heart rate as per vitals monitoring device
Mean blood pressure
Time frame: 0-4 hours
as measured by non-invasive blood pressure monitoring device
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2023.
Related trials for Pain
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Effects of Hip Hinge Exercises on Pain, Range of Motion and Functional Disability in Non-specific Low Back Pain.
Low Back Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fauzia Ali, FCPS study chair
Professor Dept of Anaesthesiology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing DEXmedetomidine and saline in people with Pain, run by Sindh Institute of Urology and Transplantation at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain score (time frame: 0-4 hours). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2023.